BDSXBiodesix, Inc.

$151M

Q2 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$20M+11.7% YoY

Gross Profit

$16M79.9% margin

Operating Income

-$10M-48.6% margin

Net Income

-$11M-57.3% margin

EPS (Diluted)

$-1.60

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$88M

Total Liabilities

$87M

Stockholders' Equity

$1M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$18M	+11.7%
Gross Profit	$16M	$14M	+13.8%
Operating Income	-$10M	-$8M	-18.0%
Net Income	-$11M	-$11M	-6.1%

Revenue Segments

Diagnostic Tests

$18M89%

Development Services

$2M11%

BDSX Q2 2025 Earnings — Biodesix, Inc. Revenue & Financial Results | Market Cap Arena